Apolipoprotein B levels in adults with type 1 diabetes not receiving lipid-lowering therapy

Clinical Biochemistry

Volumn 42, Issue 12, 2009, Pages 1218-1221

  Mazanderani, Adel B ^a   Wise, Stephanie J ^a   Tildesley, Hugh D ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Apolipoprotein B; Lipid lowering targets; Type 1 diabetes

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; GLYCOSYLATED HEMOGLOBIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN TARGETING; SEX DIFFERENCE;

ADULT; APOLIPOPROTEINS B; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED;

EID: 67650735229     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.05.013     Document Type: Article

References (19)

1. Laing S.P., Swerdlow A.J., Slater S.D., Botha J.L., Burden A.C., Waugh N.R., et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet. Med. 16 (1999) 466-471
2. Perez A., Wagner A.M., Carreras G., Gimenez G., Sanchez-Quesada J.L., Rigla M., et al. Prevalence and Phenotypic Distribution of Dyslipidemia in Type 1 Diabetes Mellitus - Effect of Glycemic Control. Arch. Intern. Med. 160 (2000) 2756-2762
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N. Engl. J. Med. 353 (2005) 2643-2653
4. Buse J. Statin Treatment in Diabetes Mellitus. Clin. Diabetes 21 (2003) 168-172
5. Pyorala K., Pedersen T.R., Kjekshus J., Faegeman O., Olsson A., and Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
6. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A.W., Livingstone S.J., et al., on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
7. Maahs D.M., Wadwa R.P., Bishop F., Daniels S.R., Rewers M., and Klingensmith G.J. Dyslipidemia in youth with diabetes: to treat or not to treat?. J. Pediatr. 153 (2008) 458-465
8. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
9. Gotto A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary event in the Air Force/Texas Coronary Atherosclerosis Prevention Study. Circulation 101 (2000) 477-484
10. De Graaf, Couture P., and Sniderman A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat. Clin. Prac. Endocrinol. Metab. 4 (2008) 608-618
11. Kastelein J.J.P., Van der Steeg W.A., Holme I., Gaffney M., Cater N.B., Barter P., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment (for the TNT and IDEAL study groups). Circulation 117 (2008) 3002-3009
12. McQueen M.J., Hawken S., Wang X., Ounpuu S., Sniderman A., Probsfield J., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372 (2008) 224-233
13. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31 (2008) 811-822
14. Canadian Diabetes Association. 2008 Clinical practice guidelines for the prevention and management of diabetes in Canada: dyslipidemia. Can. J. Diabetes 32 Supplement 1 (2008) S107-S114
15. Bachorik P.S., Lovejoy K.L., Carroll M.D., and Johnson C.L. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin. Chem. 43 (1997) 2364-2378
16. Albers J.J., Marcovina S.M., Imperatore G., Snively B.M., Stafford J., Fujimoto W.Y., et al. Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes. J. Clin. Endocrinol. Metab. 93 (2008) 735-742
17. Chaturvedi N., Fuller J.H., Taskinen M.R., and on behald of the EURODIAB PCS Group. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 14 (2001) 2071-2077
18. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
19. Wallidus G., and Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid lowering therapy. Eur. Heart J. 26 (2005) 210-212